“F-E-A-R has two meanings: 'Forget Everything And Run' or 'Face Everything And Rise.' The choice is yours.” ― Zig Ziglar
Sign Up Free Today: To comment on this article or to get and read these full articles free every day before the market open to your ‘in box’ as published, just hit the + Follow button in the upper right-hand corner of this site.
Here are four small cap stocks seeing notable analyst commentary just before we open for trading this Wednesday.
Credit Suisse is upgradingCorvus Pharmaceuticals (CRVS) from Neutral to Outperform this morning. The price target also is being raised to $15 from $11 a share previously. Credit Suisse's analyst 'believes the company's lead product, CPI-444, has a clear lead in the clinic compared to competitors, and looks like a compelling treatment for PD-1 refractory patients, a growing market with PD-1 therapy being used increasingly in first-line settings'
Leerink Partners resumes coverage of ObsEva (OBSV) with an Outperform rating and a $25 price target before the bell today. Here is the synopsis of that analyst call.
"at current levels the stock does not fully reflect the commercial potential of its lead product linzagolix, which she believes can reach over $1 billion in peak sales, its additional women's health pipeline, and its more than $100M cash balance that can fund operation into 1H20, by which time she expects to get positive UF Phase 3 data readout for linzagolix"
Free Report Available: My colleagues at Investors Alley have just published a free report entitled '10 Simple Rules To Trade Options Like A Pro' for those that want to learn more about profitably adding options strategies to their investing 'toolbox' including Buy-Writes on many of the small caps we cover in these pieces, it is now available free via download HERE.
H.C. Wainwright upgradesDicerna (DRNA) this morning moving the stock from Neutral to a Buy with a $21 price target. The reasons for the upgrade are as follows
"the first data from primary hyperoxaluria patients, due in Q3, represents a key value inflection point. Based on published preclinical data around the drug's impact on its genetic target, that the results expected likely by September are very likely to be positive"
Finally, RBC Capital is upgradingIncyte (INCY) today from a Sector Perform to an Outperform and raising its price target seven bucks a share to $79. RBC's analyst cites
"The company's "unique situation" position as a "revenue-generating, high-opex, broad-pipeline mid-cap, which should enable it to pull multiple levers" to unlock value and produce shareholder interest.' The analyst also 'points to Incyte trading near a 52-week low as a value buying opportunity, with an added possibility of being acquired by a large pharma company'
And those are four small cap concerns seeing recent analyst activity before the market opens this Hump Day. Happy Hunting.